In silico design of novel proton-pump inhibitors with reduced adverse effects

Abstract

The development of new proton-pump inhibitors (PPIs) with less adverse effects by lowering the pKa values of nitrogen atoms in pyrimidine rings has been previously suggested by our group. In this work, we proposed that new PPIs should have the following features: (1) number of ring II = number of ring I+ 1; (2) preferably five, six, or seven-membered heteroatomic ring for stability; and (3) 1<pKa1<4. Six molecular scaffolds based on the aforementioned criteria were constructed, and R groups were extracted from compounds in extensive data sources. A virtual molecule dataset was established, and the pKa values of specific atoms on the molecules in the dataset were calculated to select the molecules with required pKa values. Drug-likeness screening was further conducted to obtain the candidates that significantly reduced the adverse effects of long-term PPI use. This study provided insights and tools for designing targeted molecules in silico that are suitable for practical applications.

Keywords

proton-pump inhibitor / adverse effect / pharmacological mechanism / toxicological mechanism / pKa calculation

References

[1] Martín de Argila C. Safety of potent gastric acid inhibition. Drugs 2005; 65(Suppl 1): 97–104

[2] Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, Mitchell B, Beveridge BR, Laurence BH, Gibson GG, Grant AK, Shearman DJC, Whitehead R, Buckle PJ. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95(4): 903–912

[3] Hagiwara T, Mukaisho K, Nakayama T, Sugihara H, Hattori T. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut 2011; 60(5): 624–630

[4] Liu W, Baker SS, Trinidad J, Burlingame AL, Baker RD, Forte JG, Virtuoso LP, Egilmez NK, Zhu L. Inhibition of lysosomal enzyme activities by proton pump inhibitors. J Gastroenterol 2013; 48(12): 1343–1352

[5] Polimeni G, Cutroneo P, Gallo A, Gallo S, Spina E, Caputi AP. Rabeprazole and psychiatric symptoms. Ann Pharmacother 2007; 41(7): 1315–1317

[6] Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci 2011; 56(8): 2349–2353

[7] Bowlby HA, Dickens GR. Angioedema and urticaria associated with omeprazole confirmed by drug rechallenge. Pharmacotherapy 1994; 14(1): 119–122

[8] Wu D, Qiu T, Zhang Q, Kang H, Yuan S, Zhu L, Zhu R. Systematic toxicity mechanism analysis of proton pump inhibitors: an in silico study. Chem Res Toxicol 2015; 28(3): 419–430

[9] Landrum G. Rdkit: a software suite for cheminformatics, computational chemistry, and predictive modeling. 2013

[10] Settimo L, Bellman K, Knegtel RM. Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. Pharm Res 2014; 31(4): 1082–1095

[11] Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46(1-3): 3–26

[12] Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003; 2(2): 132–139

[13] Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, Tang A, Gabriel G, Ly C, Adamjee S, Dame ZT, Han B, Zhou Y, Wishart DS. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 2014; 42(Database issue D1): D1091–D1097

[14] Chen CY. TCM Database@Taiwan: the world’s largest traditional Chinese medicine database for drug screening in silico. PLoS One 2011; 6(1): e15939

[15] Zhu F, Shi Z, Qin C, Tao L, Liu X, Xu F, Zhang L, Song Y, Liu X, Zhang J, Han B, Zhang P, Chen Y. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 2012; 40(Database issue): D1128–D1136

[16] Reymond JL, Ruddigkeit L, Blum L, van Deursen R. The enumeration of chemical space. Wiley Interdiscip Rev Comput Mol Sci 2012; 2(5): 717–733

[17] Ruddigkeit L, van Deursen R, Blum LC, Reymond JL. Enumeration of 166 billion organic small molecules in the chemical universe database GDB-17. J Chem Inf Model 2012; 52(11): 2864–2875

[18] Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, Djoumbou Y, Mandal R, Aziat F, Dong E, Bouatra S, Sinelnikov I, Arndt D, Xia J, Liu P, Yallou F, Bjorndahl T, Perez-Pineiro R, Eisner R, Allen F, Neveu V, Greiner R, Scalbert A. HMDB 3.0 — The Human Metabolome Database in 2013. Nucleic Acids Res 2013; 41(Database issue): D801–D807

[19] Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 2012; 40(Database issue D1): D109–D114

[20] Wiener A, Shudler M, Levit A, Niv MY. BitterDB: a database of bitter compounds. Nucleic Acids Res 2012; 40(Database issue): D413–D419

[21] Ahmed J, Meinel T, Dunkel M, Murgueitio MS, Adams R, Blasse C, Eckert A, Preissner S, Preissner R. CancerResource: a comprehensive database of cancer-relevant proteins and compound interactions supported by experimental knowledge. Nucleic Acids Res 2011; 39(Database issue suppl_1): D960–D967

[22] Wishart D, Arndt D, Pon A, Sajed T, Guo AC, Djoumbou Y, Knox C, Wilson M, Liang Y, Grant J, Liu Y, Goldansaz SA, Rappaport SM. T3DB: the toxic exposome database. Nucleic Acids Res 2015; 43(Database issue): D928–D934

[23] Lim E, Pon A, Djoumbou Y, Knox C, Shrivastava S, Guo AC, Neveu V, Wishart DS. T3DB: a comprehensively annotated database of common toxins and their targets. Nucleic Acids Res 2010; 38(Database issue suppl_1): D781–D786

[24] Song H, Chu Q, Yan F, Yang Y, Han W, Zheng X. Red pitaya betacyanins protects from diet-induced obesity, liver steatosis and insulin resistance in association with modulation of gut microbiota in mice. J Gastroenterol Hepatol 2016; 31(8): 1462–1469

[25] Shelley JC, Cholleti A, Frye LL, Greenwood JR, Timlin MR, Uchimaya M. Epik: a software program for pK( a ) prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des 2007; 21(12): 681–691

[26] Klicić JJ, Friesner RA, Liu SY, Guida WC. Accurate prediction of acidity constants in aqueous solution via density functional theory and self-consistent reaction field methods. J Phys Chem A 2002; 106(7): 1327–1335

[27] Balogh GT, Gyarmati B, Nagy B, Molnar L, Keseru GM. Comparative evaluation of in silico pK(a) prediction tools on the Gold Standard Dataset. QSAR Comb Sci 2009; 28(10): 1148–1155

[28] Vellay S, Miller Latimer N, Paillard G. Interactive text mining with Pipeline Pilot: a bibliographic web-based tool for PubMed. Infect Disord Drug Targets 2009; 9(3): 366–374

[29] Rupp M, Körner R, V. Tetko I. Predicting the pKa of small molecule. Comb Chem High Throughput Screen 2011; 14(5): 307–327

[30] Grüber C, Buss V. Quantum-mechanically calculated properties for the development of quantitative structure-activity relationships (QSAR’S). pKa-values of phenols and aromatic and aliphatic carboxylic acids. Chemosphere 1989; 19(10-11): 1595–1609

[31] Walters WP, Stahl MT, Murcko MA. Virtual screening — an overview. Drug Discov Today 1998; 3(4): 160–178

[32] Bickerton GR, Paolini GV, Besnard J, Muresan S, Hopkins AL. Quantifying the chemical beauty of drugs. Nat Chem 2012; 4(2): 90–98

[33] Tian S, Wang J, Li Y, Li D, Xu L, Hou T. The application of in silico drug-likeness predictions in pharmaceutical research. Adv Drug Deliv Rev 2015; 86: 2–10

[34] Durand C, Willett KC, Desilets AR. Proton pump inhibitor use in hospitalized patients: is overutilization becoming a problem? Clin Med Insights Gastroenterol 2012; 5: CGast. S9588

RIGHTS & PERMISSIONS

Higher Education Press and Springer-Verlag GmbH Germany, part of Springer Nature